Last reviewed · How we verify
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD
The purpose of this study is to investigate the dose response of RPL554 in patients with moderate to severe CHRONIC OBSTRUCTIVE PULMONARY DISEASE that are still symptomatic despite treatment with a stable background of tiotropium over 4 weeks of treatment. This study is intended to support optimal dose selection for a Phase III program evaluating RPL554 as an add-on treatment to standard of care therapy.
Details
| Lead sponsor | Verona Pharma plc |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 416 |
| Start date | Wed May 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Nov 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- COPD
Interventions
- Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium
- Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium
- Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium
- Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium
- Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium
Countries
United States